ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Firm To Collaborate With R. W. Johnson On Vaccines.

December 1, 2000

Tafinlar Subgroup Data Shows Median OS of 20 Months

October 31, 2014

“Realistic” Bypass Budget For 1983 asks $1.147Billion; Organ Site, Training, Control Would Get No Increases

September 18, 1981

Study Section Members Likelier to Be Funded

August 1, 1986

Latest U.S. cancer statistics cover 84% of population.

December 5, 2003

NCI Grants Funding: New Funds Moved Into R01s, other Extramural Priorities

December 12, 1997